Skip to main content



) -- Adam Feuerstein's take on the biotech week that was Oct. 11, 2010:


( KG)


King Pharmaceuticals

( KG) for $3.6 billion to bolster its pain drug franchise.

Pfizer adds new partners through King Buy


(ALKS) - Get Alkermes Plc Report

CEO Richard Pops (@popsalks)

breaks company news on Twitter

. Bravo! (via @MikeHuckman)

The news broken by Pops: Finally, a drug approval in October! Alkermes received FDA clearance to market

Vivitrol as a treatment for opioid addiction

TheStreet Recommends


Alexza Pharmaceuticals



Jazz Pharmaceuticals

(JAZZ) - Get Jazz Pharmaceuticals Public Limited Company Report

not as lucky:

FDA denies approval to both of their drugs


Questcor Pharmaceuticals


receives belated FDA approval for Acthar as a treatment for infantile spasms.

The week's top-performing sector stocks:




Molecular Insight Pharmaceuticals

( MIPI) (+65%),

Rosetta Genomics



SIGA Technologies

(SIGA) - Get SIGA Technologies Inc Report

(+56%) and

King Pharmaceuticals

( KG) (+37%).

Johnson & Johnson's

(JNJ) - Get Johnson & Johnson Report

abiraterone boosts survival by four months

for patients with advanced prostate cancer.

Seattle Genetics

(SGEN) - Get Seagen, Inc. Report

reported a second clinical trial win for the lymphoma drug brentuximab vedotin.

This week's

Biotech Stock Mailbag


Exact Sciences

(EXAS) - Get Exact Sciences Corporation Report





Vanda Pharmaceuticals

(VNDA) - Get Vanda Pharmaceuticals Inc. Report


Delcath Systems




( DDSS),

Cadence Pharmaceuticals



Transcept Pharmaceuticals




Matt Herper on the

fight against drug-resistant germs


Cancer drug analyst and blogger Sally Church

spends the week at the European cancer conference known as ESMO


The week's worst-performing sector stocks:

Alexza Pharmaceuticals




(SPEX) - Get Spherix Inc. Report


AspenBio Pharma

( ANDS) (-17%),

Anadys Pharmaceuticals

( ANDS) (-16%) and

ProPhase Labs

(PRPH) - Get ProPhase Labs, Inc. Report


Cubist Pharmaceuticals


reports third quarter Cubicin sales of $154 million, lower than the consensus estimate of $162 million. The company reports higher-than-expected earnings for the quarter on lower operating expenses.

The biggest (sore) losers:

Arena Pharmaceuticals

(ARNA) - Get Arena Pharmaceuticals, Inc. Report



Chemist and blogger Derek Lowe takes another

skeptical look at the anti-aging claims

made about GlaxoSmithKline's resveratrol.

Will the withdrawal of Meridia

help or hurt other weight-loss pills

? (via Pharmalot)

Reuters Health

editor Ivan Oransky on


(GERN) - Get Geron Corporation Report

and its

first-ever stem cell study in patients with spinal cord injury


"Scrapers" are scouring web sites

looking for patients' personal information



reports weaker-than-expected sales of its three most important drugs -- Avastin, Rituxan and Herceptin. Overall, third quarter revenue fell 7%.


(IMGN) - Get ImmunoGen, Inc. Report



(NVS) - Get Novartis AG Report

strike a licensing deal to develop cancer drugs based on ImmunoGen's "armed antibody" drug delivery technology.


(EXEL) - Get Exelixis, Inc. Report

licenses two experimental cancer drugs to

Bristol-Myers Squibb

(BMY) - Get Bristol-Myers Squibb Company Report


Perfect FDA Drug Approval Pickers

Halozyme Therapeutics

(HALO) - Get Halozyme Therapeutics, Inc. Report

cut 25% of its workforce in a restructuring move.

The week in financings:

Regeneron Pharmaceuticals

(RGEN) - Get Repligen Corporation Report

($175 million),

Cytori Therapeutics


($19 million) and

Anadys Pharmaceuticals

( ANDS) ($25 million).

FDA doesn't always heed the

recommendations offered by its advisory panels

. (via @matthewherper)

Phase III data on

Titan Pharmaceuticals'


implantable addiction drug is published in JAMA


Boehringer Ingelheim

drops development of a drug for the controversial disorder known as female sexual dysfunction



(CELG) - Get Celgene Corporation Report

completes acquisition of

Abraxis BioScience


--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein


>To follow the writer on Twitter, go to


>To submit a news tip, send an email to:


Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.